Tazomeline: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Removed Category:Pyridines; Adding category Category:Tetrahydropyridines (using HotCat)
No edit summary
Line 1: Line 1:
Compound is a structural anlog of [[xanomeline]].

{{Drugbox
{{Drugbox
⚫
| IUPAC_name = 5-[4-(hexylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
| verifiedrevid =
| image = Tazomeline.png
⚫
|IUPAC_name = 5-[4-(hexylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetr​ahydropyridine
| CAS_number = 131987-54-7
| image=Tazomeline structure.png
| ATC_prefix = none
| width=
⚫
| ATC_suffix =
| CAS_number=
⚫
| PubChem = 131460
| CASNo_Ref = {{cascite}}
| ChemSpiderID = 116193
| ATC_prefix=
⚫
| C = 14 | H = 23 | N = 3 | S = 2
⚫
| ATC_suffix=
⚫
| molecular_weight = 297.48 g/mol
| ATC_supplemental=
⚫
| smiles = n2snc(/C1=C/CCN(C)C1)c2SCCCCCC
⚫
| PubChem=131460
⚫
| bioavailability =
| DrugBank=
⚫
| metabolism =
| ChemSpiderID=116193
⚫
| elimination_half-life =
⚫
| C=14 | H=23 | N=3 | S=2
⚫
| excretion =
⚫
| molecular_weight = 297.48 g/mol
⚫
| pregnancy_category =
| synonyms =
⚫
| legal_status =
⚫
| bioavailability=
⚫
| routes_of_administration =
⚫
| metabolism =
⚫
| elimination_half-life=
⚫
| excretion =
⚫
| pregnancy_category =
⚫
| legal_status =
⚫
| routes_of_administration=
⚫
| smiles = n2snc(/C1=C/CCN(C)C1)c2SCCCCCC
}}
}}

'''Tazomeline''' ('''LY-287,041''') is a [[drug]] which acts as a non-[[binding selectivity|selective]] [[muscarinic acetylcholine receptor]] [[agonist]].<ref name="pmid18082893">{{cite journal | author = Langmead CJ, Watson J, Reavill C | title = Muscarinic acetylcholine receptors as CNS drug targets | journal = Pharmacology & Therapeutics | volume = 117 | issue = 2 | pages = 232–43 | year = 2008 | month = February | pmid = 18082893 | doi = 10.1016/j.pharmthera.2007.09.009 | url = http://linkinghub.elsevier.com/retrieve/pii/S0163-7258(07)00207-0}}</ref><ref name="doi10.1517/13543784.9.10.2259">{{cite journal | author = Amos D Korczyn | title = Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease | journal = Expert Opinion on Investigational Drugs | volume = 9 | issue = 10 | pages = 2259–2267(9) | year = 2000 | month = October | doi = 10.1517/13543784.9.10.2259 | url = http://www.ingentaconnect.com/content/apl/eid/2000/00000009/00000010/art00004}}</ref> It was in [[clinical trial]]s for the treatment of [[cognitive deficit|cognitive dysfunction]] such as that seen in [[Alzheimer's disease]] and [[schizophrenia]], but development was apparently scrapped for unknown reasons.<ref name="pmid18082893">{{cite journal | author = Langmead CJ, Watson J, Reavill C | title = Muscarinic acetylcholine receptors as CNS drug targets | journal = Pharmacology & Therapeutics | volume = 117 | issue = 2 | pages = 232–43 | year = 2008 | month = February | pmid = 18082893 | doi = 10.1016/j.pharmthera.2007.09.009 | url = http://linkinghub.elsevier.com/retrieve/pii/S0163-7258(07)00207-0}}</ref><ref name="doi10.1517/13543784.9.10.2259">{{cite journal | author = Amos D Korczyn | title = Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease | journal = Expert Opinion on Investigational Drugs | volume = 9 | issue = 10 | pages = 2259–2267(9) | year = 2000 | month = October | doi = 10.1517/13543784.9.10.2259 | url = http://www.ingentaconnect.com/content/apl/eid/2000/00000009/00000010/art00004}}</ref><ref name="doi10.1023/A:1010474325601">{{cite journal | author = Mashkovskii MD, Glushkov RG | title = Drugs for the Treatment of Alzheimer's Disease | journal = Pharmaceutical Chemistry Journal | volume = 35 | issue = 4 | pages = 179–182 | year = 2001 | month = April | doi = 10.1023/A:1010474325601 | url = http://www.springerlink.com/content/w5vq328733t2v601/}}</ref>

== See also ==
* [[Alvameline]]
* [[Cevimeline]]
* [[Milameline]]
* [[Sabcomeline]]
* [[Talsaclidine]]
* [[Xanomeline]]


== References ==
== References ==
{{Reflist|2}}
{{Reflist}}




Line 38: Line 40:


[[Category:Muscarinic agonists]]
[[Category:Muscarinic agonists]]
⚫
[[Category:Tetrahydropyridines]]
[[Category:Thiadiazoles]]
[[Category:Thiadiazoles]]
⚫
[[Category:Tetrahydropyridines]]


{{nervous-system-drug-stub}}

Revision as of 06:21, 14 September 2010

Tazomeline
Clinical data
ATC code
  • none
Identifiers
  • 5-[4-(hexylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H23N3S2
Molar mass297.48 g/mol g·mol−1
3D model (JSmol)
  • n2snc(/C1=C/CCN(C)C1)c2SCCCCCC

Tazomeline (LY-287,041) is a drug which acts as a non-selective muscarinic acetylcholine receptor agonist.[1][2] It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but development was apparently scrapped for unknown reasons.[1][2][3]

See also

References

  1. ^ a b Langmead CJ, Watson J, Reavill C (2008). "Muscarinic acetylcholine receptors as CNS drug targets". Pharmacology & Therapeutics. 117 (2): 232–43. doi:10.1016/j.pharmthera.2007.09.009. PMID 18082893. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. ^ a b Amos D Korczyn (2000). "Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease". Expert Opinion on Investigational Drugs. 9 (10): 2259–2267(9). doi:10.1517/13543784.9.10.2259. {{cite journal}}: Unknown parameter |month= ignored (help)
  3. ^ Mashkovskii MD, Glushkov RG (2001). "Drugs for the Treatment of Alzheimer's Disease". Pharmaceutical Chemistry Journal. 35 (4): 179–182. doi:10.1023/A:1010474325601. {{cite journal}}: Unknown parameter |month= ignored (help)


Template:Nootropics

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tazomeline&oldid=384734698"